![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EFNA1 |
Gene summary for EFNA1 |
![]() |
Gene information | Species | Human | Gene symbol | EFNA1 | Gene ID | 1942 |
Gene name | ephrin A1 | |
Gene Alias | B61 | |
Cytomap | 1q22 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P20827 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1942 | EFNA1 | GSM4909282 | Human | Breast | IDC | 1.08e-20 | 5.19e-01 | -0.0288 |
1942 | EFNA1 | GSM4909286 | Human | Breast | IDC | 1.27e-02 | -1.78e-01 | 0.1081 |
1942 | EFNA1 | GSM4909296 | Human | Breast | IDC | 4.36e-04 | -1.34e-01 | 0.1524 |
1942 | EFNA1 | GSM4909297 | Human | Breast | IDC | 1.64e-12 | -3.33e-01 | 0.1517 |
1942 | EFNA1 | GSM4909301 | Human | Breast | IDC | 3.69e-42 | 8.12e-01 | 0.1577 |
1942 | EFNA1 | GSM4909304 | Human | Breast | IDC | 2.06e-04 | -3.52e-01 | 0.1636 |
1942 | EFNA1 | GSM4909308 | Human | Breast | IDC | 4.11e-08 | 3.63e-01 | 0.158 |
1942 | EFNA1 | GSM4909311 | Human | Breast | IDC | 2.92e-25 | -2.98e-01 | 0.1534 |
1942 | EFNA1 | GSM4909312 | Human | Breast | IDC | 1.17e-05 | 1.23e-01 | 0.1552 |
1942 | EFNA1 | GSM4909319 | Human | Breast | IDC | 3.65e-28 | -3.00e-01 | 0.1563 |
1942 | EFNA1 | GSM4909321 | Human | Breast | IDC | 3.24e-07 | -6.71e-02 | 0.1559 |
1942 | EFNA1 | brca2 | Human | Breast | Precancer | 1.33e-04 | 3.34e-01 | -0.024 |
1942 | EFNA1 | brca3 | Human | Breast | Precancer | 3.60e-02 | 2.84e-01 | -0.0263 |
1942 | EFNA1 | brca7 | Human | Breast | Precancer | 2.56e-02 | 6.36e-01 | -0.009 |
1942 | EFNA1 | brca10 | Human | Breast | Precancer | 4.25e-12 | 5.64e-01 | -0.0029 |
1942 | EFNA1 | M1 | Human | Breast | IDC | 1.82e-03 | -3.92e-01 | 0.1577 |
1942 | EFNA1 | NCCBC11 | Human | Breast | DCIS | 2.34e-02 | -4.63e-01 | 0.1232 |
1942 | EFNA1 | NCCBC14 | Human | Breast | DCIS | 5.32e-06 | -4.04e-01 | 0.2021 |
1942 | EFNA1 | NCCBC3 | Human | Breast | DCIS | 9.36e-09 | -3.84e-01 | 0.1198 |
1942 | EFNA1 | NCCBC5 | Human | Breast | DCIS | 4.41e-15 | -5.66e-01 | 0.2046 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00702421 | Esophagus | ESCC | thymocyte apoptotic process | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
GO:00480133 | Esophagus | ESCC | ephrin receptor signaling pathway | 33/8552 | 51/18723 | 4.77e-03 | 1.85e-02 | 33 |
GO:19029597 | Esophagus | ESCC | regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
GO:00336281 | Esophagus | ESCC | regulation of cell adhesion mediated by integrin | 31/8552 | 48/18723 | 6.41e-03 | 2.35e-02 | 31 |
GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
GO:001635816 | Esophagus | ESCC | dendrite development | 130/8552 | 243/18723 | 8.33e-03 | 2.95e-02 | 130 |
GO:19052457 | Esophagus | ESCC | regulation of aspartic-type peptidase activity | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:00031793 | Esophagus | ESCC | heart valve morphogenesis | 34/8552 | 55/18723 | 1.16e-02 | 3.90e-02 | 34 |
GO:00031703 | Esophagus | ESCC | heart valve development | 39/8552 | 65/18723 | 1.41e-02 | 4.59e-02 | 39 |
GO:0070231 | Esophagus | ESCC | T cell apoptotic process | 31/8552 | 50/18723 | 1.48e-02 | 4.79e-02 | 31 |
GO:00421767 | Liver | NAFLD | regulation of protein catabolic process | 83/1882 | 391/18723 | 2.94e-11 | 1.01e-08 | 83 |
GO:19030507 | Liver | NAFLD | regulation of proteolysis involved in cellular protein catabolic process | 53/1882 | 221/18723 | 1.32e-09 | 2.34e-07 | 53 |
GO:19033627 | Liver | NAFLD | regulation of cellular protein catabolic process | 56/1882 | 255/18723 | 1.38e-08 | 1.71e-06 | 56 |
GO:00098957 | Liver | NAFLD | negative regulation of catabolic process | 65/1882 | 320/18723 | 2.50e-08 | 2.71e-06 | 65 |
GO:00316477 | Liver | NAFLD | regulation of protein stability | 61/1882 | 298/18723 | 5.00e-08 | 4.71e-06 | 61 |
GO:00313307 | Liver | NAFLD | negative regulation of cellular catabolic process | 55/1882 | 262/18723 | 9.35e-08 | 7.59e-06 | 55 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:00315896 | Liver | NAFLD | cell-substrate adhesion | 65/1882 | 363/18723 | 2.84e-06 | 1.18e-04 | 65 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa040152 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa040154 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa040155 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa040158 | Colorectum | CRC | Rap1 signaling pathway | 48/1091 | 210/8465 | 4.00e-05 | 8.70e-04 | 5.90e-04 | 48 |
hsa043606 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Breast | DCIS |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Cervix | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Cervix | CC |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Cervix | CC |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | AD |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | CRC | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | FAP |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | Healthy |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | MSI-H |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | MSI-H |
EFNA1 | EPHA5 | EFNA1_EPHA5 | EPHA | CRC | MSI-H |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | MSS |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Endometrium | AEH |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | Endometrium | AEH |
Page: 1 2 3 4 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EFNA1 | SNV | Missense_Mutation | novel | c.154N>G | p.Pro52Ala | p.P52A | P20827 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
EFNA1 | SNV | Missense_Mutation | rs755272713 | c.115N>G | p.Ile39Val | p.I39V | P20827 | protein_coding | tolerated(1) | benign(0) | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
EFNA1 | SNV | Missense_Mutation | rs760965678 | c.416N>T | p.Arg139Leu | p.R139L | P20827 | protein_coding | tolerated(0.2) | benign(0.04) | TCGA-AA-A02K-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD |
EFNA1 | SNV | Missense_Mutation | c.500C>T | p.Ala167Val | p.A167V | P20827 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
EFNA1 | SNV | Missense_Mutation | rs548758015 | c.328N>T | p.Arg110Cys | p.R110C | P20827 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
EFNA1 | SNV | Missense_Mutation | novel | c.496C>A | p.Leu166Ile | p.L166I | P20827 | protein_coding | tolerated(0.3) | benign(0.017) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EFNA1 | SNV | Missense_Mutation | c.415N>T | p.Arg139Cys | p.R139C | P20827 | protein_coding | deleterious(0.04) | possibly_damaging(0.6) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD | |
EFNA1 | SNV | Missense_Mutation | novel | c.200N>G | p.Tyr67Cys | p.Y67C | P20827 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
EFNA1 | SNV | Missense_Mutation | rs762981577 | c.184N>A | p.Ala62Thr | p.A62T | P20827 | protein_coding | tolerated(0.61) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
EFNA1 | SNV | Missense_Mutation | novel | c.551N>T | p.Ala184Val | p.A184V | P20827 | protein_coding | deleterious(0.03) | possibly_damaging(0.79) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |